
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
In late April, the investigational tyrosine kinase inhibitor (TKI) zongertinib (Boehringer Ingelheim) was the star of the annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, with results for the phase 1a/1b …